-
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
inFerring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
-
Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic
inFerring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A…
-
Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)
in…
-
Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
inPivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in…
-
Ferring Pharmaceuticals and Blackstone Life Sciences restructure novel gene therapy collaboration
inFerring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted…
-
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
inFerring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted…
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
inFerring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022…
-
Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally
inFerring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees…
-
Ferring Announces New Collaboration for Development of Olamkicept
inFerring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
inNew subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.
PRESS RELEASE 2022
PRESS RELEASE 2022